Albert Hoenekopp
About
Albert Hoenekopp is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, Albert Hoenekopp has authored 21 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 16 papers in Genetics and 6 papers in Rheumatology. Recurrent topics in Albert Hoenekopp's work include Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Acute Myeloid Leukemia Research (7 papers). Albert Hoenekopp is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Acute Myeloid Leukemia Research (7 papers). Albert Hoenekopp collaborates with scholars based in Switzerland, Germany and Italy. Albert Hoenekopp's co-authors include Timothy P. Hughes, Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Hagop M. Kantarjian, Neil J. Gallagher, Dong‐Wook Kim, Gabriel Étienne, Ricardo Pasqüini and Richard E. Clark and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Albert Hoenekopp
21 papers receiving 1.8k citations
Hit Papers
Peers
Albert Hoenekopp
P. Le Coutre Germany
Beatriz Moiraghi Argentina
Athena Countouriotis United States
Concepción Boqué Spain
Anna Turkina Russia
M. Brigid Bradley‐Garelik United States
Philippe Rousselot France
Philipp D. le Coutre Germany
Lydia Wunderle Germany
P. Rae United States
Citations per year, relative to Albert Hoenekopp Albert Hoenekopp (= 1×)
peers
P. Le Coutre
Countries citing papers authored by Albert Hoenekopp
Since
Specialization
Citations
This map shows the geographic impact of Albert Hoenekopp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Hoenekopp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Hoenekopp more than expected).
Fields of papers citing papers by Albert Hoenekopp
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Albert Hoenekopp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Hoenekopp. The network helps show where Albert Hoenekopp may publish in the future.
Co-authorship network of co-authors of Albert Hoenekopp
This figure shows the co-authorship network connecting the top 25 collaborators of Albert Hoenekopp. A scholar is included among the top collaborators of Albert Hoenekopp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Hoenekopp. Albert Hoenekopp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Reinhardt, Dirk, et al.. (2019). Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 3835–3835.
2.
Döhner, Hartmut, Jorge Sierra, Richard M. Stone, et al.. (2018). Trial in Progress: A Phase 3, Randomized, Double-Blind Study of Midostaurin in Combination with Chemotherapy and as Single-Agent Maintenance Therapy in Newly Diagnosed Patients with FLT3 Mutation–Negative Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia. 18. S206–S207.
3.
Santini, Valeria, Pierre Fenaux, Aristoteles Giagounidis, et al.. (2016). Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood. 128(22). 225–225.
4.
Santini, Valeria, Arlene S. Swern, Aristoteles Giagounidis, et al.. (2015). 115 MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q). Leukemia Research. 39. S59–S59.
5.
Santini, Valeria, Ana G. Almeida, Aristoteles Giagounidis, et al.. (2015). 116 THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL. Leukemia Research. 39. S60–S60.
6.
Almeida, António, Valeria Santini, Anna Jonášová, et al.. (2015). Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). Blood. 126(23). 2880–2880.
7.
Santini, Valeria, António Almeida, Aristoteles Giagounidis, et al.. (2014). Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood. 124(21). 409–409.
8.
Hochhaus, Andreas, Giuseppe Saglio, Richard A. Larson, et al.. (2013). Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 121(18). 3703–3708.
9.
Hochhaus, Andreas, Timothy P. Hughes, Giuseppe Saglio, et al.. (2012). Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood. 120(21). 167–167.
10.
Kantarjian, Hagop M., Andreas Hochhaus, Giuseppe Saglio, et al.. (2011). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology. 12(9). 841–851.
11.
Larson, Richard A., Udomsak Bunworasate, Anna Turkina, et al.. (2011). Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,. Blood. 118(21). 3768–3768.
12.
Saglio, Giuseppe, Ricardo Pasqüini, Saengsuree Jootar, et al.. (2011). Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. Blood. 118(21). 452–452.
13.
Hughes, Timothy P., Dong‐Wook Kim, Gabriel Étienne, et al.. (2011). The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up. Blood. 118(21). 2755–2755.
14.
Hochhaus, Andreas, Gert J. Ossenkoppele, Josy Reiffers, et al.. (2011). Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. Blood. 118(21). 114–114.
15.
Larson, Richard A., Phillipp D. Le Coutre, Josy Reiffers, et al.. (2010). Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.. Journal of Clinical Oncology. 28(15_suppl). 6501–6501.
16.
Saglio, Giuseppe, Dong‐Wook Kim, Surapol Issaragrisil, et al.. (2010). Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine. 362(24). 2251–2259.
17.
Larson, Richard A., Andreas Hochhaus, Giuseppe Saglio, et al.. (2010). Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. Blood. 116(21). 2291–2291.
18.
Hughes, Timothy P., Andreas Hochhaus, Giuseppe Saglio, et al.. (2010). ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). Blood. 116(21). 207–207.
19.
Hughes, Timothy P., Phillipp D. Le Coutre, Richard E. Clark, et al.. (2010). Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd.. Journal of Clinical Oncology. 28(15_suppl). 6556–6556.
20.
Saglio, Giuseppe, Dong-Wook Kim, Surapol Issaragrisil, et al.. (2009). Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial. Blood. 114(22). LBA–1.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by P. Le Coutre Breakdown of academic impact, for papers by Beatriz Moiraghi Breakdown of academic impact, for papers by Athena Countouriotis Breakdown of academic impact, for papers by Concepción Boqué Breakdown of academic impact, for papers by Anna Turkina Breakdown of academic impact, for papers by M. Brigid Bradley‐Garelik Breakdown of academic impact, for papers by Philippe Rousselot Breakdown of academic impact, for papers by Philipp D. le Coutre Breakdown of academic impact, for papers by Lydia Wunderle Breakdown of academic impact, for papers by P. Rae